Keywords: glaxosmithkline, pulls, back, levitra, co-promotion, deal, bayer
GlaxoSmithKline pulls back from Levitra co-promotion deal with Bayer
Article | 17 January 2005
UK drug giant GlaxoSmithKline has transferred the majority of its Levitra (vardenafil) co-promotion rights back to Germany's Bayer HealthCare for 208 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
